Aminophylline Injection, Solution
Product Images NDC 51662-1204

Aminophylline injection is a medication administered intravenously and distributed by Hospira, Inc. Each 10 mL of the solution contains 250 mg of aminophylline (25 mg/mL), which should be protected from light and not used if crystals have separated from the solution. The pH level of the solution is 8.8 (86 to 9.0), and it may contain an excess of ethylenediamine for pH adjustment. Each mL of the solution contains 25 mg of aminophylline (calculated as the dihydrate), which is equivalent to 19.7 mg/mL of anhydrous theophylline. The solution is sterile and nonpyrogenic, but any unused portion should be discarded. The usual dose should be determined according to the insert.*

Aminophylline Injection, USP 250mg (25mg/mL) is available in a 10mL vial. The National Drug Code for the product is 51662-1204-2 and the lot number is ABCDEFGHIJKLMNOPQRST with an expiration date of June 1, 2021. The product should not be used if crystals have separated from solution and must be used promptly after dilution using aseptic technique. The solution should be mixed thoroughly and used only if clear and seal in intact and undamaged. The unused portion should be discarded, and the product must be protected from light, stored at 20 to 25°C (68 to 77°F). The manufacturer's package insert provides additional information. The product is distributed by HF Acquisition Co., LLC, Mukilteo, WA 98275.*

Aminophylline injection is a medication that comes in a 250mg (25mg/mL) solution, packaged in 10mL vials in a box containing 25 vials. The National Drug Code (NDC) for this medication is 51662-1204-3 and the lot number is ABCDEFGHIJKLMNOPQRST with an expiration date of June 1, 2021. It is recommended to use aseptic technique when administering via intravenous route, and to ensure the solution is mixed thoroughly and crystal-free. The solution should only be used if it is clear and the seal is intact. The product should be protected from light and stored at a temperature between 20-25°C (68-77°F). The manufacturer's package insert can provide more information about the medication. This medication is only available via prescription, and it is distributed by HF Acquisition Co., LLC.*

This appears to be a chart showing the signs and symptoms of acute and chronic drug overdose based on two different studies, with the number of patients experiencing each symptom listed under each study. The symptoms are divided into categories such as gastrointestinal, metabolic/other, cardiovascular, and neurologic, among others. It is not clear what drug or drugs are being studied.*

This is a description of a medication in the form of a 10 mL single-dose injection. Each mL of the injection contains aminophylline, which is calculated to be 25 mg equivalent to 19.7 mg/mL of anhydrous theophylline. The injection may contain an excess of ethylenediamine for pH adjustment. The pH level of the injection is between 8.6 to 9.0. The injection is sterile and nonpyrogenic, with a warning to store it away from light. The unused portion should be discarded and it should not be used if crystals have separated from the solution. The medication is intended for L.V. use and the usual dose can be found in the insert.*

This is a chart that shows the mean and range of total body clearance and half-life for different populations grouped by age and physiological state. Data is provided for premature neonates, term infants, children, adults, elderly, and for individuals with concurrent illnesses or altered physiological state such as acute pulmonary edema, COPD, cystic fibrosis, liver disease, pregnancy, sepsis, and thyroid disease. The remaining fields with no data are labeled as not available.*

This appears to be dosing guidance for a medication based on weight and age, divided into different categories based on whether the patient is a child, adolescent or adult. The dosage varies depending on the severity of the patient's condition, including whether they have cardiac or liver dysfunction or are experiencing multiorgan failure or shock. The exact medication and purpose is not clear from this text.*

This text provides guidelines for adjusting dosage based on peak serum concentration for the medication theophylline. The guidelines specify infusion rate changes based on the concentration range and whether symptoms are controlled or adverse effects are present. The recommended actions range from increasing infusion rate to treating overdose.*

This text appears to be a description of the Unit of Sale and Concentration of a medication. The medication is available in two different strengths: 250mg/10mL and 500mg/20mL. The concentration of both strengths is 25mg/mL. Each unit of sale is a carton containing 25 vials of the medication. The NDC codes for the two strengths are also provided.*

This document lists drug interactions with theophylline, a medication used to treat respiratory conditions. The interactions include drugs that can increase or decrease the clearance of theophylline, alter its efficacy, and/or cause adverse effects. Some of the drugs listed include alcohol, erythromycin, and verapamil. The nature of these interactions varies from inhibiting enzymes or receptors to pharmacologic synergy. Some interactions may require dosage adjustments or discontinuation of theophylline.*

This is a list of medicines grouped by name, including albuterol, amoxicillin, atenolol, azithromycin, caffeine, cefaclor, co-trimoxazole, diltiazem, dirithromycin, enflurane, famotidine, felodipine, finasteride, hydrocortisone, isoflurane, isoniazid, isradipine, influenza vaccine, ketoconazole, lomefloxacin, mebendazole, medroxyprogesterone, methylprednisolone, metronidazole, metoprolol, nadolol, nifedipine, nizatidine, norfloxacin, ofloxacin, omeprazole, prednisone, prednisolone, ranitidine, rifabutin, roxithromycin, sorbitol, sucralfate, terbutaline, terfenadine, tetracycline, and tocainide.*